Japan's JERA agrees to buy LNG from Cheniere, Sempra-February 2024-www.financetom.com

Japan's JERA agrees to buy LNG from Cheniere, Sempra

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Japan's JERA agrees to buy LNG from Cheniere, Sempra

Jun 11, 2025 3:11 PM

WASHINGTON, June 11 (Reuters) -

JERA, Japan's largest power utility, has agreed to buy up to

5.5 million metric tons per annum of U.S. liquefied natural gas

under 20 year contracts, with deliveries starting around 2030,

U.S. and JERA officials said on Wednesday.

JERA agreed to buy 1.5 mtpa from Sempra's ( SRE ) Port

Arthur LNG Phase 2 project and up to 1 mtpa from Cheniere

, they said. The remaining volume comes from recently

announced agreements.

Previous page： Nvidia Isn't the Only Way to Play AI Next page： Johnson & Johnson Closes Acquisition of Shockwave Medical

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Nvidia Isn't the Only Way to Play AI

May 31, 2024

09:23 AM EDT, 05/31/2024 (MT Newswires) -- Nvidia ( NVDA ) remains the dominant play in AI in the near-term, but there are other ways to play the AI story, according to The Compound and Friends podcast on Friday morning. Host Josh Brown says Nvidia ( NVDA ) will become larger than Apple ( AAPL ) on a market...

Johnson & Johnson Closes Acquisition of Shockwave Medical

May 31, 2024

09:26 AM EDT, 05/31/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday that it has closed its acquisition of Shockwave Medical, which it said will operate as a business unit within Johnson & Johnson MedTech. The transaction is anticipated to dilute adjusted earnings per share by about $0.10 in 2024 and $0.17 in 2025 considering the impact...

Novartis Says Late-Stage Scemblix Trial Meets Primary Endpoints

May 31, 2024

09:23 AM EDT, 05/31/2024 (MT Newswires) -- Novartis ( NVS ) said Friday that the late-stage trial for its treatment for chronic myeloid leukemia, Scemblix, has met both of its primary endpoints. Scemblix demonstrated clinically significant efficacy that was better than select standard-of-care therapies of the same type, the drugmaker said. The drug's safety profile was consistent with previous studies...

Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer

May 31, 2024

On Thursday, Gilead Sciences Inc ( GILD ) announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC). The TROPiCS-04 study evaluated Trodelvy (sacituzumab govitecan-hziy; SG) vs. single-agent chemotherapy (treatment of physicians’ choice, TPC) in patients with mUC who have previously received platinum-containing chemotherapy and anti-PD-(L)1 therapy. Also Read: Gilead’s Aggressive Push Beyond...